36 related articles for article (PubMed ID: 37864958)
21. Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update.
Pierri F; Faraci M; Giardino S; Dufour C
Expert Rev Hematol; 2021 Oct; 14(10):911-925. PubMed ID: 34488529
[TBL] [Abstract][Full Text] [Related]
22. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
23. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi S; Niederwieser D; Ahmed SO; Sanz J; Mohty M; Aljurf M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):575-580. PubMed ID: 35418351
[TBL] [Abstract][Full Text] [Related]
24. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
25. Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.
Zhang ZH; Lian XY; Yao DM; He PF; Ma JC; Xu ZJ; Guo H; Zhang W; Lin J; Qian J
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1853-1864. PubMed ID: 28470473
[TBL] [Abstract][Full Text] [Related]
26. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
27. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
Kanda Y
Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.
Sabile J; Pavletic S; Migdady Y
Cancer J; 2023 May-Jun 01; 29(3):179-187. PubMed ID: 37195774
[TBL] [Abstract][Full Text] [Related]
29. [Development of acute myeloid leukemia in a myelodysplastic syndrome patient after allogeneic hematopoietic stem cell transplantation for 12 years: a case report and literature review].
Li Z; Zhang Y; Zhou J; Fang B; Lin Q; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):63-5. PubMed ID: 24602738
[No Abstract] [Full Text] [Related]
30. Myelodysplastic syndromes complicating hematopoietic stem cell transplantation.
Fassas AB; Tricot G
Cancer Treat Res; 2001; 108():169-84. PubMed ID: 11702599
[No Abstract] [Full Text] [Related]
31. A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
Notarantonio AB; Roth-Guépin G; Bonmati C; Divoux M; Kicki C; Pagliuca S; Campidelli A; Rubio MT; D'Aveni-Piney M
Leuk Res; 2023 Dec; 135():107405. PubMed ID: 37864958
[No Abstract] [Full Text] [Related]
32. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
[TBL] [Abstract][Full Text] [Related]
33. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
34. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
35. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
36. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]